As bioMérieux’s Global Center of Excellence for Molecular Diagnostics, no other company has FDA-cleared and CE-IVD marked assays for more pathogens. Although rapid antigen testing offers quick. However, further research is needed to determine its optimal use in the evaluation of patients with suspected ME. With more than 25 years of molecular experience, BioFire Diagnostics, LLC sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing. Current diagnostic techniques for the detection and identification of respiratory viruses are somewhat limited.
![biofire diagnostics biofire diagnostics](https://img.medicalexpo.com/pt/images_me/photo-g/93999-11668101.jpg)
This newer rapid diagnostic tool has an overall high sensitivity and specificity for the diagnosis of ME with a fast turnaround time and has the potential to improve resource utilization for patients presenting with suspicion of ME.
![biofire diagnostics biofire diagnostics](https://ix-cdn.b2e5.com/images/52820/52820_17ecc79449e747aa938b701ab1b9d34d_1522692836.png)
The BioFire FilmArray Meningitis/Encephalitis Panel was the first Food and Drug Administration-cleared multiplex polymerase chain reaction for the evaluation of cerebrospinal fluid samples, able to identify 14 organisms in a single test reaction. Multiplexed polymerase chain reaction panels are one of several rapid diagnostic technologies that have the potential to overcome some of the limitations of conventional diagnostic methods for ME. Patients suspected of having ME are often hospitalized and started on empiric antimicrobial treatment, because of the potential adverse consequences of delaying the diagnosis or treatment. View the company’s relaunched website.Meningitis and encephalitis (ME) are important causes of morbidity and mortality worldwide. Under the agreement, bioMrieux will pay 450. The Company has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research and military markets. Founded in 1990, the Company currently holds over 70 patents related to polymerase chain reaction (PCR), including rapid PCR cycling. BioFire also is continuing to develop biosurveillance products such as its PCR-based biodetection system RAZOR EX and the FilmArray BioSurveillance System. French diagnostics giant bioMrieux finalized its acquisition of U.S.-based BioFire Diagnostics on Thursday. BioFire Diagnostics is a privately held clinical diagnostics company based in Salt Lake City, Utah. In addition to the FilmArray RP, BioFire is developing similar FilmArray panels for pathogen identification in blood culture, gastrointestinal infections, meningitis, and more. BioFire now provides the only FDA-cleared clinical diagnostic test for eight of the 20 organisms in its panel. The FilmArray Respiratory Panel (RP) is FDA-cleared for 20 viral and bacterial respiratory pathogens. BioFire Diagnostics is a privately held clinical diagnostics company based in Salt Lake City, Utah. We have established strong momentum in the diagnostics marketplace, and the new branding under BioFire Diagnostics better reflects the markets we serve.”īioFire Diagnostics will continue to focus on leveraging its FilmArray pathogen detection system to develop multiplex diagnostic tests for various clinical applications. “The new name highlights our expanded presence in the clinical diagnostics market. “We are excited to announce our new name to our customers and industry members,” says Kirk Ririe, Chief Executive Officer of BioFire Diagnostics. The company has also relaunched its website to reveal its new branding. The agreement to purchase BioFire was first announced on September 4. More than 200 growth achievement in 2021. Awarded as the Product Manager of the Year (2021) in ASEAN East.
![biofire diagnostics biofire diagnostics](https://www.biofiredx.com/wp-content/uploads/2019/03/SyndromicTesting.jpg)
Awarded as Country and Franchise of the Year for 2020.
![biofire diagnostics biofire diagnostics](https://img.medicalexpo.fr/images_me/photo-g/93999-11668138.jpg)
The new name reflects the growing breadth of the company’s service in molecular diagnostics. Marcy l'Etoile, France, JanubioMrieux, a world leader in the field of in vitro diagnostics, announces that it has finalized its acquisition of 100 ownership in BioFire Diagnostics Inc., a privately held U.S.-based company specialized in molecular biology. ASEAN EAST (Philippines, Guam & Pacific Islands) Top Achievements: Instrumental in the success of Biofire Franchise in ASEAN East. With just one test you can identify pathogens more than 9 out of 10 positive blood cultures in about 1 hour with only 2 minutes of hands-on time. Idaho Technology, Inc., has announced it has changed the corporate name to BioFire Diagnostics, Inc. The BIOFIRE ® Blood Culture Identification 2 (BCID2) Panel tests for a comprehensive list of 33 pathogens and 10 antibiotic resistance genes associated with bloodstream infections.